Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients.

ABSTRACT:

Background

The role of patient age in the efficacy of mesenchymal stem cell (MSC) therapy in ischemic cardiomyopathy (ICM) is controversial.

Objectives

This study sought to determine whether the therapeutic effect of culture-expanded MSCs persists, even in older subjects.

Methods

Patients with ICM who received MSCs via transendocardial stem cell injection (TESI) as part of the TAC-HFT (Transendocardial Autologous Cells in Ischemic Heart Failure) (n = 19) and POSEIDON (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis) (n = 30) clinical trials were divided into 2 age groups: younger than 60 and 60 years of age and older. Functional capacity was measured by 6-min walk distance (6MWD) and quality of life using the Minnesota Living With Heart Failure Ques

SUBMITTER: Golpanian S 

PROVIDER: S-EPMC4405121 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature